Activation of GPBAR1 by BAR501, a selective synthetic agonist, reduces vascular inflammation and atherosclerosis in a mouse model of NAFLD-related cardiovascular disease

The purpose of this study was to evaluate the effect of GPBAR1 activation in a mouse model of atherosclerosis. For this study, Apolipoprotein E deficient mice (ApoE−/−), a standard model of atherosclerosis, were fed with HFD-F alone or in combination with BAR501 for 14 weeks and then sacrificed. The transcriptome analysis of the aorta showed an anti-inflammatory activity of BAR501 that downregulated the expression of many genes belonging to inflammatory pathways.